# Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

> **NCT02355379** · PHASE3 · RECRUITING · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 774 (estimated)

## Conditions studied

- Colonic Adenocarcinoma

## Interventions

- **DRUG:** LV5FU2 or capectitabine
- **DRUG:** FOLFOX4 or XELOX
- **OTHER:** Observation
- **DRUG:** LV5FU2 or capecitabine

## Key facts

- **NCT ID:** NCT02355379
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-08
- **Target enrollment:** 774 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02355379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02355379, "Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02355379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*